India's Sun Pharma to conduct clinical trial of pancreatitis drug in COVID-19 patients

Drugmaker Sun Pharmaceutical Industries Ltd said on Friday that it received Indian regulatory approval to start clinical trials of pancreatitis drug nafamostat mesilate in COVID-19 patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2BbeSrz
via IFTTT